EUCTR2018-000416-21-ES进行中（未招募）1 期
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •_Participants must be at least 18 years old;
- •_have histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease
- •_Have at least 1 lesion accessible for biopsy;
- •_Eastern Cooperative Oncology Group Performance Status of 0 or 1;
- •_Participants must have received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to solid tumor histologies.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 225
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 75
排除标准
- •_Participants with primary CNS malignancies or tumors with CNS metastases as the only site of disease;
- •_Participants with other active malignancy requiring concurrent intervention;
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2018-000416-21-FIBristol-Myers Squibb International Corporation435
进行中（未招募）
1 期
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000416-21-PLBristol-Myers Squibb International Corporation435
进行中（未招募）
1 期
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and inCombination with Nivolumab in Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2018-000416-21-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO450
进行中（未招募）
1 期
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2018-000416-21-DEBristol-Myers Squibb International Corporation450
进行中（未招募）
1 期
A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid TumorsAdvanced Solid TumorsMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2018-000416-21-ROBristol-Myers Squibb International Corporation435